[Glucagon-like peptide-1 analogues and cardiovascular risk factors: evidence from clinical trials].
Glucagon-like peptide-1 (GLP-1) receptor agonists, which have been recently introduced as a treatment for type 2 diabetes, show several features which could be useful for the prevention of cardiovascular disease. In fact, beyond reducing hyperglycemia with low hypoglycemic risk, these drugs are capable of promoting a relevant weight loss. Furthermore, in trials performed in type 2 diabetes, GLP-1 analogues determine a consistent reduction in blood pressure and a modest improvement of lipid profile. Therefore, their overall effect on cardiovascular risk appears to be very beneficial. This expectation is confirmed, up to now, by the observation that the incidence of cardiovascular events in randomized trial shows a trend towards a greater reduction than that expected on the basis of the improvement of metabolic control. Specifically designed randomized trials, which are currently ongoing, will provide greater information in the next few years.